Drug Profile
AST 301
Alternative Names: AST-301; EP-301; HER2-ICD vaccine; pNGVL3-hICDLatest Information Update: 04 Aug 2023
Price :
$50
*
At a glance
- Originator EpiThany; University of Washington
- Developer Aston Science; University of Washington
- Class Antigens; Antineoplastics; Cancer vaccines; Immunotherapies; Vaccines
- Mechanism of Action Th1 cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer; Gastric cancer
- No development reported Ovarian cancer
Most Recent Events
- 04 Jul 2023 Phase-II Conerstone3 trial in Gastric cancer (In adults, In the elderly, Mid-stage disease, Second-line therapy or greater) in Taiwan (Parenteral) (NCT05771584)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intradermal, Injection)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intradermal, Injection)